Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Millennium Management LLC

Millennium Management LLC raised its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 53.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,980,906 shares of the company's stock after acquiring an additional 1,043,228 shares during the period. Millennium Management LLC owned about 5.01% of Pyxis Oncology worth $4,650,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. raised its position in Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock worth $939,000 after buying an additional 219,100 shares during the last quarter. Graham Capital Management L.P. bought a new position in Pyxis Oncology in the 4th quarter worth approximately $47,000. Caption Management LLC bought a new position in Pyxis Oncology in the 4th quarter worth approximately $35,000. Bank of America Corp DE boosted its stake in Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after purchasing an additional 9,062 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $35,000. Institutional investors own 39.09% of the company's stock.

Analysts Set New Price Targets

PYXS has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $8.00 target price on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Monday, May 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded up $0.04 on Monday, hitting $1.25. 207,272 shares of the company's stock were exchanged, compared to its average volume of 739,969. The firm's 50-day moving average is $1.07 and its 200 day moving average is $1.41. The company has a market capitalization of $77.13 million, a PE ratio of -1.21 and a beta of 1.15. Pyxis Oncology, Inc. has a 1-year low of $0.83 and a 1-year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). On average, analysts anticipate that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.